
    
      This study was designed to evaluate the bioequivalence of a single oral dose of 2 different
      drug forms of TAK-536 pediatric formulation (dry syrup, granules) and a single oral dose of
      TAK-536 commercial tablet by using open-label, 2 Ã— 2 crossover design.
    
  